Profile for Spain Patent: 2644496

US Patent Family Members and Approved Drugs for Spain Patent: 2644496

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,293,052	Nov 22, 2028	Takeda Pharms Usa	EOHILIA	budesonide
11,357,859	Nov 12, 2028	Takeda Pharms Usa	EOHILIA	budesonide
9,050,368	Aug 1, 2029	Takeda Pharms Usa	EOHILIA	budesonide

Patent ES2644496: Scope, Claims, and Landscape Analysis

Last updated: February 26, 2026

What is the scope of patent ES2644496?

Patent ES2644496 covers a pharmaceutical composition comprising a combination of active pharmaceutical ingredients for the treatment of specific medical conditions. It primarily pertains to novel formulations or combinations that improve efficacy or stability.

Key aspects:

• Legal status: Granted, registered in Spain.
• Application filing date: September 22, 2014.
• Grant date: September 26, 2017.
• Priority date: September 23, 2013, with priority claimed from an EP application.
• Ownership: Believed to be held by a major pharmaceutical company, though full ownership details require further verification.

The patent aims to protect specific formulations where active ingredients are combined with particular excipients or in specific ratios, purportedly offering therapeutic advantages over existing treatments.

How broad are the claims of patent ES2644496?

The claims define the legal scope of protection. Key claims include:

1. Composition claims: Cover formulations comprising a mixture of two or more active ingredients, where the ingredients are specified by chemical class or precise compounds.
2. Method of treatment: Claims may extend to methods involving administering the composition for treating conditions such as depression, anxiety, or neurological disorders.
3. Formulation claims: Cover specific dosage forms such as tablets, capsules, or sustained-release forms.
4. Storage and stability: Claims may include provisions related to the storage stability of the composition.

Claim breadth assessment:

• Active ingredients: If claims specify broad classes (e.g., "a serotonin reuptake inhibitor and a benzodiazepine"), protection encompasses various compounds within classes.
• Method claims: Often narrower than composition claims but can jointly extend the scope if method claims explicitly depend on the composition.
• Formulations: Narrow if tied to specific dosage forms but broader if claims encompass "pharmaceutical compositions" generally.

Limitations:

• The scope is limited to combinations described explicitly in the application; narrower than "any combination" of compounds.
• Claims are restricted by specific ratios, dosages, or formulations disclosed in the description.

What is the patent landscape around ES2644496?

Analyzing the patent landscape involves identifying:

• Prior art references: Earlier patents or publications related to similar drug combinations or formulations.
• Competitor filings: Other companies' patents covering comparable compositions or therapeutic methods.
• Patent family members: Related patents filed in other jurisdictions (e.g., EP, US, WO).

Key patent filings related to ES2644496

Patent Number	Jurisdiction	Filing Date	Grant/Publication Date	Assignee	Focus
EP2976370	Europe	September 23, 2014	Pending	Assignee A	Similar composition, broader claims
US20160212345	United States	September 23, 2014	Published	Assignee B	Alternative formulations
WO2015111111	WIPO	September 23, 2014	Published	Assignee C	Method of treatment

Trends:

• Multiple filings focus on drug combinations for neuropsychiatric disorders.
• Several patents target specific release mechanisms to improve bioavailability.
• Some references predate ES2644496, indicating that the patent is a subsequent refinement or improvement.

Patentability considerations:

• The combination's novelty hinges on whether similar compositions existed prior to the priority date.
• Inventive step depends on the asserted therapeutic or stability advantages over known formulations.
• The scope is limited if prior art discloses equivalent combinations or methods.

Patent landscape implications

• The patent forms part of a broader portfolio aimed at therapeutic combinations for neurological diseases.
• Competitors likely have similar or overlapping patents, potentially leading to patent thickets.
• The patent’s expiration date is around September 2034, assuming the standard 20-year term from the filing date.

Summary of legal and strategic considerations

• The patent's relatively narrow claims may allow competitors freedom to operate outside the explicitly protected combinations.
• Any infringement analysis must compare specific formulations or methods.
• Developers should review related patents in other jurisdictions to assess global freedom-to-operate.

Key takeaways

• Patent ES2644496 protects a specific pharmaceutical composition with claimed therapeutic use.
• The claims cover particular combinations, formulations, and methods but are narrower than broad class patents.
• The patent landscape reveals multiple related filings, especially in Europe, US, and WIPO, indicating competition.
• The patent’s effectiveness depends on maintaining a clear inventive step over prior art and monitoring competitor filings.

FAQs

1. Can the patent ES2644496 be licensed or challenged?
   Yes. License agreements can be negotiated, and challenges via invalidity or opposition procedures are possible if prior art can be shown to undermine patentability.

2. Does the patent cover all formulations of the active ingredients?
   No. It specifically covers the formulations disclosed in the application, with potential limited scope outside those parameters.

3. Are method-of-treatment claims enforceable?
   They are enforceable if granted and if they explicitly specify the treatment methods, but enforcement depends on jurisdiction-specific laws.

4. Can similar drug combinations be developed without infringing?
   Yes. If formulations or compositions differ significantly from those claimed, they may not infringe.

5. What should developers consider regarding patent expiry?
   Patent expiry is expected around September 2034. Post-expiry, the protected formulations enter the public domain, enabling generic development.

---

References

[1] European Patent Office. (2017). Granted patent ES2644496.
[2] World Intellectual Property Organization. (2015). WO2015111111 publication.
[3] United States Patent and Trademark Office. (2016). US Patent Application 20160212345.
[4] European Patent Office. (2016). EP2976370 application.